If you or a loved one has been diagnosed with Alzheimer’s disease, or a physician suspects it may be Alzheimer’s disease, you or they may be eligible to participate in a clinical research study. RefocusALZ is a new clinical trial for Alzheimer’s disease. The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Association (FDA), or any regulatory agency, for the treatment of any condition.
To be considered for the RefocusALZ study, patients must:
Other criteria will apply. There is no cost to the patient to participate in the RefocusALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.
Do not discontinue any medicine unless you are advised to do so by the study center staff or your primary care physician.
There is no cost to you or your insurance provider for participating in this study. If you qualify for this study, study-related care may be provided at no cost to you.
No, health insurance is not required in order to participate.
There may be potential risks to participating in this study. All drugs and medical procedures carry a risk of side effects; therefore, it is possible that participants may experience some discomfort or other reactions from use of the study drug. If you decide to participate, the study staff will explain the potential risks to you before any study procedures are conducted.
Participants may or may not receive any benefit from being in this study. It is possible that participants may get better, stay the same, or get worse. In the future, other people with mild cognitive impairment or mild dementia associated with Parkinson’s disease or prodromal or manifest Lewy body dementia may be helped by this research.